Details once dismissed as trivial—like timing—can quietly reshape cancer care.
Sometimes stepping back isn’t a setback — it’s a reset.
The best medicine isn’t always treatment—it’s honesty, and the chance to live the life you choose.
Sometimes restraint is the wiser choice — half of patients are cured with PD-1 alone.
Curated science + real conversations = faster, safer implementation on Monday.
A hopeful reflection on RP1’s FDA setback and the future of intratumoral therapy in melanoma.
When innovation meets immune activation, new possibilities emerge for melanoma care.
Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.
Hope isn’t always about cure — sometimes, it’s just the strength to try.
Rare immune toxicities can be fatal—but timely recognition and aggressive care can change the outcome.